FDA product-center directors wouldn't comment on whether any alternative user-fee provisions were under consideration during a March 21 Senate hearing, despite a recent budget blueprint from the Trump administration that appears to seek more user fees from companies next year than what industry agreed to in recent negotiations.
FDA Device Center Director Jeffrey Shuren testified before the Senate Health, Education, Labor and Pensions (HELP) Committee on the medical device user-fee agreement, alongside drug evaluation center director Janet Woodcock and center for biologics evaluation director Peter Marks